SCHEMBL3911560

SCHEMBL3911560

O=c1[nH]n(CC(F)(F)F)c2ccc(NS(=O)(=O)c3ccc(F)c(C(F)(F)F)c3)cc12

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTPN2 P17706 4/20 0.45
PTPN1 P18031 4/20 0.45
PTPN5 P54829 4/20 0.45
HSPD1 P10809 2/20 0.45
HSPE1 P61604 2/20 0.45
ERAP1 Q9NZ08 3/20 0.45
TP53 P04637 5/20 0.43
LMNA P02545 2/20 0.43
THRB P10828 1/20 0.43
MAPT P10636 2/20 0.42
SLC22A12 Q96S37 1/20 0.42
PGAM1 P18669 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
PKM P14618 2/20 0.41
HTT P42858 1/20 0.40
CCR2 P41597 1/20 0.40
FFAR4 Q5NUL3 2/20 0.39
CCR9 P51686 1/20 0.39
FFAR1 O14842 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3906902 0.91 ERAP1 (0.44) PTPN2PTPN1PTPN5HSPD1HSPE1
SCHEMBL3906955 0.87 PTPN2 (0.43) PTPN2PTPN1PTPN5HSPD1HSPE1
SCHEMBL3916191 0.87 PTPN2 (0.43) PTPN2PTPN1PTPN5HSPD1HSPE1
SCHEMBL1809970 0.87 FFAR1 (0.45) PTPN2PTPN1PTPN5HSPD1HSPE1
SCHEMBL1812321 0.87 PTPN2 (0.49) PTPN2PTPN1PTPN5HSPD1HSPE1
SCHEMBL1843321 0.87 FFAR4 (0.43) PTPN2PTPN1PTPN5HSPD1HSPE1
SCHEMBL3908576 0.87 PTPN2 (0.42) PTPN2PTPN1PTPN5HSPD1HSPE1
SCHEMBL3915268 0.86 TP53 (0.46) PTPN2PTPN1PTPN5HSPD1HSPE1
SCHEMBL3903951 0.86 PTPN2 (0.42) PTPN2PTPN1PTPN5HSPD1HSPE1
SCHEMBL1809138 0.85 PTPN2 (0.41) PTPN2PTPN1PTPN5HSPD1HSPE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7528158-B2 Indazolone derivatives useful as 11b-HSD1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2009-05-05 US claimed
EP-1797042-B1 INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS HOFFMANN LA ROCHE (CH) 2009-01-07 EP claimed
US-20060069269-A1 Novel indazolone derivatives useful as 11b-HSD1 inhibitors F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2006-03-30 US claimed
US-7528158-B2 Indazolone derivatives useful as 11b-HSD1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2009-05-05 US disclosed
EP-1797042-B1 INDOZOLONE DERIVATIVES AS 11B-HSD1 INHIBITORS HOFFMANN LA ROCHE (CH) 2009-01-07 EP disclosed
US-20060069269-A1 Novel indazolone derivatives useful as 11b-HSD1 inhibitors F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2006-03-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060069269-A1 Novel indazolone derivatives useful as 11b-HSD1 inhibitors HSD17B1, HSD11B1, HSD17B7 PTPN2 3791/4885PTPN1 2907/4885PTPN5 3577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.